CureDM, Inc. is a biopharmaceutical company based in Wilmington, DE, dedicated to developing innovative therapies for diabetes. Their research team has discovered a groundbreaking human peptide, known as Human proIslet Peptide (HIP), which stimulates the regeneration of insulin-producing islets in the pancreas. By utilizing this peptide therapeutic, CureDM aims to restore pancreatic function in diabetic patients without the need for stem cells.
CureDM's approach involves partnering with established pharmaceutical companies for the licensing and distribution of their products. With a focus on preventing, ameliorating, and potentially reversing diabetes, CureDM is at the forefront of developing new treatments that may lead to the discontinuation of insulin use.
Generated from the website